trans-Vaccenic acid是一种单不饱和脂肪酸，是反刍动物来源的脂质中最主要的一种反式异构体。
Cas No.:693-72-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
trans-Vaccenic acid is a kind of monounsaturated fatty acid which is the predominant trans isomer found in ruminant fats [1]. trans-Vaccenic acid is the primary precursor for endogenous synthesis of cis-9, trans-11 conjugated linoleic acid in animals and humans [1]. trans-Vaccenic acid exerts anti-inflammatory effects and helps alleviate complications associated with metabolic diseases [2]. trans-Vaccenic acid has been suggested as a beneficial effect in reducing the incidence of heart disease, cancer, and obesity in recent study [3].
trans-Vaccenic acid (0, 50, 100 and 200μM; 72h) inhibited the cell viability of MCF-7 cells in a dose-dependent manner [3]. trans-Vaccenic acid (0, 25, 50 and 100μM; 24h) significantly decreased p-Akt levels and Bad phosphorylation on Ser-136 and Ser-112 of NPC cells [4].
trans-Vaccenic acid (1% in diet; 11~15d; p.o.) increased CD8+ T cell population in tumour-infiltrating lymphocytes (TILs) in C57BL/6 mice implanted with B16F10 tumor [5]. trans-Vaccenic acid (1% in diet; 16 weeks; p.o.) reduced plasma triglyceride (TG), total cholesterol (TC), LDL cholesterol and nonesterified fatty acids (NEFA) concentrations in obese JCR:LA-cp rats [1].
References:
[1] Wang Y, Jacome-Sosa M M, Ruth M R, et al. Trans-11 vaccenic acid reduces hepatic lipogenesis and chylomicron secretion in JCR:LA-cp rats [J]. The Journal of nutrition, 2009, 139(11): 2049-2054.
[2] Cristina M O, Elizabeth B R, Jose R M, et al. Mechanisms and therapeutic potential of key anti-inflammatory metabiotics: trans-vaccenic acid, indole-3-lactic acid, thiamine, and butyric acid [J]. Probiotics and antimicrobial proteins, 2025, 17(5): 2805-2018.
[3] Lim J N, Oh J J, Wang T, et al. trans-11 18:1 vaccenic acid (TVA) has a direct anti-carcinogenic effect on MCF-7 human mammary adenocarcinoma cells [J]. Nutrients, 2014, 6(2): 627-636.
[4] Song J, Wang Y, Fan X, et al. Trans-vaccenic acid inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells via a mitochondrial-mediated apoptosis pathway [J]. Lipids in health and disease, 2019, 18(1): 46.
[5] Fan H, Xia S, Xiang J, et al. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity [J]. Nature, 2023, 623(7989): 1034-1043.
trans-Vaccenic acid是一种单不饱和脂肪酸，是反刍动物来源的脂质中最主要的一种反式异构体[1]。trans-Vaccenic acid是动物和人类内源性合成cis-9, trans-11共轭亚油酸的重要前体物质[1]。trans-Vaccenic acid具有抗炎作用，并有助于缓解与代谢性疾病相关的并发症[2]。近期有研究表明trans-Vaccenic acid具有降低心脏病、癌症和肥胖症发病率的积极作用[3]。
trans-Vaccenic acid（0、50、100和200μM；72h）以浓度依赖的方式抑制MCF-7细胞的细胞活力[3]。trans-Vaccenic acid（0、25、50和100μM；24h）显著降低NPC细胞的p-Akt水平和Ser-136、Ser-112上的Bad的磷酸化水平[4]。
trans-Vaccenic acid（1% in diet；11~15d；p.o.）增加了植入B16F10肿瘤的C57BL/6小鼠的肿瘤浸润淋巴细胞（TILs）中的CD8+ T细胞数量[5]。trans-Vaccenic acid（1% in diet；16 weeks；p.o.）降低了肥胖JCR:LA-cp大鼠血浆中的甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇以及非酯化脂肪酸（NEFA）的浓度[1]。
| Cell experiment [1]: | |
Cell lines | MCF-7 cells |
Preparation Method | MCF-7 cells were treated with different concentrations of trans-Vaccenic acid for 72h, fatty acid-free bovine serum albumin as a vehicle. Cell proliferation was evaluated using an MTT assay. |
Reaction Conditions | 0, 50, 100 and 200μM; 72h |
Applications | trans-Vaccenic acid inhibited the cell viability of MCF-7 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male obese JCR:LA-cp rats |
Preparation Method | At 8 weeks of age, obese rats were randomized into two groups and were fed for 16 weeks either a lipid balanced control diet (CD) or an isocaloric lipid balanced diet containing 1.0% (wt:wt) trans-Vaccenic acid. At 24 weeks of age, rats were killed and plasma and serum samples were collected from the left ventricle for analysis. |
Dosage form | 1% in diet; 16 weeks; p.o. |
Applications | trans-Vaccenic acid reduced plasma triglyceride (TG), total cholesterol (TC), LDL cholesterol and nonesterified fatty acids (NEFA) concentrations compared with CD-fed obese rats. |
References: | |
| Cas No. | 693-72-1 | SDF | |
| 别名 | 反式-11-十八烯酸 | ||
| Canonical SMILES | CCCCCC/C=C/CCCCCCCCCC(O)=O | ||
| 分子式 | C18H34O2 | 分子量 | 282.46 |
| 溶解度 | DMSO: ≥ 250 mg/mL (885.08 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5403 mL | 17.7016 mL | 35.4032 mL |
| 5 mM | 708.1 μL | 3.5403 mL | 7.0806 mL |
| 10 mM | 354 μL | 1.7702 mL | 3.5403 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet